Armata Pharmaceuticals Inc. (ARMP)
NYSE: ARMPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ARMP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $112.69M
- EPS (TTM)
- -$4.17
- Dividend yield
- None
- 52-week range
- 2.40 – 14.98
- Day range
- 2.89 – 3.19
- Volume / Avg
- 85.64K / 182.52K
- Beta
- —
- Shares outstanding
- 37.19M
52-week range
ARMP stock today
On Nov 20, ARMP ended the session at $3.03, adding $0.05 (1.68%), versus the S&P 500's 3.70% decline. Trading was light, with 85.64K shares changing hands, about 47% of the average daily volume. At this level, ARMP sits near the bottom of its 52-week range of $2.40 to $14.98: 79.8% below the high, set on Apr 22, 2026 and 26.2% above the low.
ARMP is down 51.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.9%. Armata Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.17), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Armata Pharmaceuticals
Company profileArmata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Deborah L. Birx M.D.
- Headquarters
- Los Angeles, CA
- Employees
- 61
- Website
- armatapharma.com
Financial highlights
Full financialsArmata Pharmaceuticals reported a net loss of $173.8 million, compared with a loss of $18.9 million a year earlier. Diluted earnings per share came in at -$4.80.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-173.80M | $-18.92M | $-69.05M | $-36.92M | $-23.16M |
| EPS (diluted) | $-4.80 | $-0.89 | $-1.91 | $-1.08 | $-0.96 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$17.50+477.56%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.24 vs $-0.57
- Surprise
- +57.89%
ARMP news
All ARMP newsArmata Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs ARMP |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs ARMP |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs ARMP |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs ARMP |
| HUMAHumacyte Inc. | 0.4454 | -17.90% | $123.73M | vs ARMP |
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs ARMP |
| MOLNMolecular Partners AG ADR | 2.53 | -5.25% | $96.80M | vs ARMP |
| IPHAInnate Pharma S.A. ADS | 0.8634 | -8.14% | $96.44M | vs ARMP |
Indexes, lists and sector
Armata Pharmaceuticals stock FAQ
What is Armata Pharmaceuticals's stock price today?
ARMP last traded at $3.03 as of Nov 20, 4:00 PM EST, up 1.68% on the day. Prices are delayed at least 15 minutes.
Does Armata Pharmaceuticals pay a dividend?
No. Armata Pharmaceuticals does not currently pay a regular cash dividend.
Who is Armata Pharmaceuticals's CEO?
Dr. Deborah L. Birx M.D. is the chief executive officer of Armata Pharmaceuticals Inc., which has about 61 employees.
Has ARMP ever split its stock?
Yes. The most recent ARMP stock split was a 1-for-14 split on May 10, 2019, one of 4 splits on record.
What is the ARMP 52-week high?
The 52-week high for ARMP is $14.98 and the 52-week low is $2.40. The stock is currently 79.8% below its high.